CDK2 inhibitor

DRUG CLASS:

CDK2 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

IDH2 mutation	Glioma	IDH2 mutation	Glioma	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-06873600 Sensitive: C2 – Inclusion Criteria PF-06873600 Sensitive : C2	PF-06873600 Sensitive: C2 – Inclusion Criteria PF-06873600 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	INX-315 Sensitive: C2 – Inclusion Criteria INX-315 Sensitive : C2	INX-315 Sensitive: C2 – Inclusion Criteria INX-315 Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-07104091 Sensitive: C2 – Inclusion Criteria PF-07104091 Sensitive : C2	PF-07104091 Sensitive: C2 – Inclusion Criteria PF-07104091 Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	TQB3616 Sensitive: C2 – Inclusion Criteria TQB3616 Sensitive : C2	TQB3616 Sensitive: C2 – Inclusion Criteria TQB3616 Sensitive : C2
IDH1 mutation	Glioma	IDH1 mutation	Glioma	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3
MCL1 amplification	Endometrial Cancer	MCL1 amplification	Endometrial Cancer	CYC065 Sensitive: C3 – Early Trials CYC065 Sensitive : C3	CYC065 Sensitive: C3 – Early Trials CYC065 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	BLU-222 Sensitive: C3 – Early Trials BLU-222 Sensitive : C3	BLU-222 Sensitive: C3 – Early Trials BLU-222 Sensitive : C3
CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D
CCNE1 amplification	Breast Cancer	CCNE1 amplification	Breast Cancer	CDK2 inhibitor Sensitive: D – Preclinical CDK2 inhibitor Sensitive : D	CDK2 inhibitor Sensitive: D – Preclinical CDK2 inhibitor Sensitive : D
CD133 positive	Glioblastoma	CD133 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D
CD44 positive	Glioblastoma	CD44 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D
BRCA1 2080delA + CCNE1 overexpression	Breast Cancer	BRCA1 2080delA + CCNE1 overexpression	Breast Cancer	CYC065 Sensitive: D – Preclinical CYC065 Sensitive : D	CYC065 Sensitive: D – Preclinical CYC065 Sensitive : D
BRCA1 2080delA	Breast Cancer	BRCA1 2080delA	Breast Cancer	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D
BRCA1 R1443*	Breast Cancer	BRCA1 R1443*	Breast Cancer	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D	olaparib + CYC065 Sensitive: D – Preclinical olaparib + CYC065 Sensitive : D
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib + BLU-222 Sensitive: D – Preclinical ribociclib + BLU-222 Sensitive : D	ribociclib + BLU-222 Sensitive: D – Preclinical ribociclib + BLU-222 Sensitive : D
CCNE1 amplification	Gastric Cancer	CCNE1 amplification	Gastric Cancer	INX-315 Sensitive: D – Preclinical INX-315 Sensitive : D	INX-315 Sensitive: D – Preclinical INX-315 Sensitive : D
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib + BLU-222 Sensitive: D – Preclinical palbociclib + BLU-222 Sensitive : D	palbociclib + BLU-222 Sensitive: D – Preclinical palbociclib + BLU-222 Sensitive : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TQB3616 Sensitive: D – Preclinical TQB3616 Sensitive : D	TQB3616 Sensitive: D – Preclinical TQB3616 Sensitive : D

CDK2 inhibitor

CDK2 inhibitor

Associations(21)

Associations
(21)